DGAP-News: Press Release 4SC AG: 4SC Discovery and CRELUX enter into strategic alliance
(firmenpresse) - DGAP-News: 4SC AG / Key word(s): Alliance
Press Release 4SC AG: 4SC Discovery and CRELUX enter into strategic
alliance
18.04.2012 / 07:30
---------------------------------------------------------------------
Press Release
4SC Discovery and CRELUX enter into a strategic alliance for joint drug
discovery services
Planegg-Martinsried, 18 April 2012 - The biotech company 4SC AG (Frankfurt,
Prime Standard: VSC) announced that its drug discovery affiliate 4SC
Discovery GmbH and CRELUX GmbH, a leading company for protein
crystallography services, have entered into a strategic partnership for
integrated drug discovery services. Both partners are adding core
competencies to a joint discovery platform geared towards comprehensive
drug discovery services under one roof. Pharma and Biotech customers will
get quick and affordable high quality services for the discovery and
optimization of novel small molecule drugs.
The integrated drug discovery platform i2c (idea to candidate) offers a
seamless process from early concept through to a preclinical development
candidate ready to advance into formal animal model testing and thereafter
into clinical trials. The i2c client groups are pharma companies looking to
outsource part of their early discovery projects and also small and
mid-size biotech companies lacking the relevant infrastructure. Besides the
standard fee-for service offerings i2c also includes research
collaborations based on risk sharing models including milestones and
royalties. These collaborations are provided as tailor made solutions for
smaller sized companies and interested pharma partners.
4SC and CRELUX have a long and successful track record in the discovery and
development of novel drugs. Both partners are adding their synergistic
competencies to i2c. CRELUX is a leading company in advancing innovations
in protein production, crystallography and compound screening. Next to its
strong in silico screening and medicinal chemistry capacities, 4SC
Discovery adds to that a team of experienced pharmacologists that has
successfully brought a number of small molecule drugs from discovery to
clinical trials. As one example, 4SC's proprietary in silico screening
technology can test the activity potential of millions of substances,
selecting promising candidates for further iterations of optimisation in
the lab and at the computer.
Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief
Scientific Officer of 4SC AG, noted: 'This partnership is of high strategic
value to 4SC Discovery. With CRELUX we have found a competent and highly
synergistic technology partner well known to us. By adding their
competencies - especially in protein production and crystallization - we
are able to offer much broader services to our customers and even cover the
complete drug discovery value chain. With this alliance we aim to generate
additional business and to further strengthen our business model and the
one of our parent company 4SC AG.'
'Joining with 4SC Discovery allows us to immediately offer more
comprehensive drug discovery services and thus is perfectly covering a very
important strategic goal of CRELUX. We are working with 4SC since many
years and efficiently executed a number of drug discovery projects. The
established processes and the door-to-door location of both companies will
now also accelerate our joint customer projects. Looking at the current
drug discovery landscape we are convinced that the i2c platform will
contribute significantly to the discovery projects of our customers' added
Dr. Michael Schaeffer, Executive Director and Co-founder of CRELUX.
Ends
About 4SC Discovery
4SC Discovery GmbH is a wholly-owned subsidiary of 4SC AG that offers
technologies and tailored research services covering drug discovery and
chemical optimisation through to a preclinical development candidate. The
company focuses its services on offering customers in the pharmaceutical,
biotech and chemical industries the cost and time-to-market benefits that
result from a drug discovery and optimisation process based on a powerful,
computer-aided, screening and discovery platform. In addition, 4SC
Discovery also applies its comprehensive pharmacological expertise to
investigating new compounds in the areas of cancer and autoimmune disease -
a measure also intended to further enhance the clinical development
pipeline for the 4SC Group. 4SC Discovery aims to engage in partnerships
with pharmaceutical and biotech companies to accelerate the development of
its research programmes and further advance their commercialisation.
About 4SC Group
The Group managed by 4SC AG (ISIN DE0005753818, Frankfurt Prime Standard:
VSC) discovers and develops targeted small-molecule drugs for the treatment
of diseases with a high unmet medical need in various autoimmune and cancer
indications. These drugs are intended to provide patients with innovative
treatment options that are more tolerable and efficacious than existing
therapies, and provide a better quality of life. At the end of 2011, 4SC
Group had 96 employees. The company was founded in 1997.
About CRELUX
CRELUX (www.crelux.com) specializes in tailor made protein and protein
crystallography drug discovery services. The company is a professional and
dedicated service provider for the global pharma and biotech industry.
CRELUX is privately owned with no venture capital or other external
investment and is therefore fully independent of external shareholders. The
company is solely committed to long-term development and growth with all
profit being re-invested into the business.
CRELUX is a client focused provider with a portfolio of premium drug
discovery services based on our top level protein expertise. In our PRIME
PROTEIN programs we are advancing innovations in protein expression to
promote the availability of high quality proteins for use in assays,
diagnostics and crystallization. Our XPRESS portfolio of readily available
crystallographic targets grants turn-around times within a few weeks. Our
XPERT crystallography services from concept to high resolution complex
structure are provided under individual agreements following our customer's
needs. In addition we are offering compound and fragment screening based on
our unique screening technology INTRACT. Finally, our i2c (idea to
candidate) service includes target to hit and concept to early development
candidate fee-for-service projects.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
For more information please visit www.4sc.de or www.4sc-discovery.de or
www.crelux.com or contact directly:
4SC AG
Jochen Orlowski, Investor Relations&Public Relations
jochen.orlowski(at)4sc.com, Tel.: +49 (0) 89 70 07 63 66
Bettina v. Klitzing-Stückle, Corporate Communications
bettina.von.klitzing(at)4sc.com, Tel.: +49 (0) 89 70 07 63 0
MC Services
Raimund Gabriel
raimund.gabriel(at)mc-services.eu , Tel.: +49 (0) 89 21 02 28 30
Mareike Mohr
mareike.mohr(at)mc-services.eu, Tel.: +49 (0) 89 21 02 28 40
The Trout Group (USA)
Chad Rubin
Crubin(at)troutgroup.com, Tel.: +1 646 378 2947
CRELUX GmbH
Dr. Michael Schaeffer, Executive Director Strategy&Business
schaeffer(at)crelux.com, Tel.: +49 (0) 89 70 07 60 170
End of Corporate News
---------------------------------------------------------------------
18.04.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Germany
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public(at)4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
165359 18.04.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Greenvironment and SAACKE present new product for high-efficient steam generation at the Hanover Fair
Datum: 18.04.2012 - 07:30 Uhr
Sprache: Deutsch
News-ID 136209
Anzahl Zeichen: 12106
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 237 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Press Release 4SC AG: 4SC Discovery and CRELUX enter into strategic alliance"
steht unter der journalistisch-redaktionellen Verantwortung von
4SC AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
